# LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)

> **NCT04889404** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 130 (actual)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04889404
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-22
- **Primary completion:** 2025-02-06
- **Final completion:** 2025-02-06
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04889404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04889404, "LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04889404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*